Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

Michel Brodbeck has worked on the following 89 EPO patent applications which have been published in the last five years:

EP10798236

ANTIBODY FORMULATION

IPC classification:
A61K 9/00, A61K 39/395, A61K 47/18, A61K 47/26, C07K 16/22
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11705420

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

IPC classification:
A61K 47/48, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11711425

ANTI-LRP6 ANTIBODIES

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11711232

COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS

IPC classification:
A61K 39/395, A61K 47/10
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP11723145

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, G01N 33/50
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11738852

IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR

IPC classification:
G01N 33/534, G01N 33/60
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11731614

ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE

IPC classification:
C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION WITHDRAWN
EP10798080

PHARMACEUTICAL COMPOSITIONS COMPRISING IGF-1 PROTEINS, A BUFFERING AND A TONICITY AGENT

IPC classification:
A61K 9/00, A61K 9/08, A61K 38/30
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11776994

METHODS AND COMPOSITIONS FOR MODULATING THE WNT PATHWAY

IPC classification:
A61K 38/08, A61K 38/10, A61P 19/08, A61P 19/10, C07K 7/06, C07K 7/08
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11785527

PREDICTING PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION USING A POLYGENIC SCORE

IPC classification:
C12Q 1/68, G06F 19/18
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP11781498

COMBINATION OF BEVACIZUMAB AND 2,2-DIMETHYL-N-((S)-6-OXO-6,7-DIHYDRO - 5H-DIBENZO[B,D]AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUORO-PROPYL)-MALONAMIDE FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

IPC classification:
A61K 31/55, A61K 39/395, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP12709485

TREATMENT OF DISORDERS WITH ALTERED VASCULAR BARRIER FUNCTION

IPC classification:
A61K 31/00, A61K 38/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12722058

FGFR1 AGONISTS AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 3/10, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP11845574

METHODS FOR DETECTING NEURODEGENERATIVE DISEASES OR DISORDERS

IPC classification:
C12Q 1/68, G01N 33/53, G01N 33/58, G01N 33/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12751691

NEUREGULIN ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12750781

RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

IPC classification:
C12Q 1/68
Applicant:
VIB VZW
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Life Sciences Research Partners VZW
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12750601

METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY

IPC classification:
C12Q 1/68
Applicant:
VIB VZW
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Life Sciences Research Partners VZW
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12178248

Compositions and methods for the prevention of oxidative degradation of proteins

IPC classification:
A61K 38/29, A61K 47/18, A61K 47/26
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP12842985

THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA

IPC classification:
A61K 38/00, A61K 39/395, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP12788199

RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

IPC classification:
C12Q 1/68
Applicant:
VIB VZW
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Life Sciences Research Partners VZW
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11787363

METHODS OF PURIFYING POLYPEPTIDES

IPC classification:
A61K 38/00, C07K 1/16, C07K 1/18, G01N 30/02, G01N 31/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
The patent has been granted
EP12809640

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

IPC classification:
G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12795799

ANTIBODY FORMULATION

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12806322

ION EXCHANGE MEMBRANE CHROMATOGRAPHY

IPC classification:
C07K 1/18
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Genentech, Inc.
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP12816206

ARTICLES OF MANUFACTURE AND METHODS FOR CO-ADMINISTRATION OF ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/08, C07K 16/32
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13736138

BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS

IPC classification:
A61K 39/00, A61K 39/395, C12Q 1/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13701352

ANTI-LRP5 ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, G01N 33/50
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Genentech, Inc.
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13706133

R-SPONDIN TRANSLOCATIONS AND METHODS USING THE SAME

IPC classification:
C07K 14/415
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11781418

TREATMENT METHODS

IPC classification:
A61K 31/337, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12763521

NOVEL PROTEIN PURIFICATION METHODS

IPC classification:
C07K 1/34, C12N 7/00, C12N 7/02
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Genentech, Inc.
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13713295

IMPROVED HARVEST OPERATIONS FOR RECOMBINANT PROTEINS

IPC classification:
C12P 21/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13715815

ANTI-HCMV IDIOTYPIC ANTIBODIES AND USES THEREOF

IPC classification:
C07K 16/42, G01N 33/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13714129

DIAGNOSIS AND TREATMENTS RELATING TO HER3 INHIBITORS

IPC classification:
C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13769258

DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER

IPC classification:
A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
no data provided
Status:
EXAMINATION IN PROGRESS
EP13189711

Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer

IPC classification:
A61K 31/337, A61K 31/513, A61K 31/675, A61K 31/704, A61K 39/395, A61K 45/06, A61P 35/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Christopher Marcus Denison, Mewburn Ellis LLP
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP13729174

METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS

IPC classification:
A61K 39/395, C07K 16/22, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Genentech, Inc.
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14193190

Tumor tissue based biomarkers for bevacizumab combination therapies

IPC classification:
A61K 39/395, G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13730890

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

IPC classification:
A61K 35/00, G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13733496

METHODS FOR INACTIVATION OF VIRUSES AND BACTERIA IN CELL CULTURE MEDIA

IPC classification:
C12N 5/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP12704198

Fc VARIANTS AND METHODS FOR THEIR PRODUCTION

IPC classification:
C07K 16/00
Applicant:
F. Hoffmann-La Roche AG
Applicant:
Genentech, Inc.
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13734091

CELL PENETRATING PEPTIDES TO TARGET EIF4E

IPC classification:
C07K 14/47
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11701059

TUMOR TISSUE BASED BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES

IPC classification:
A61K 39/395, G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13751040

ANTI-JAGGED ANITBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13748450

COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA

IPC classification:
A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
Christopher Marcus Denison, Mewburn Ellis LLP
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13763162

METHODS AND COMPOSITIONS FOR PRODUCING INDUCED HEPATOCYTES

IPC classification:
C12N 5/071, G01N 33/50
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13773482

METHODS AND COMPOSITIONS FOR PREVENTING NORLEUCINE MISINCORPORATION INTO PROTEINS

IPC classification:
C12N 9/10, C12P 21/02, C12R 1/19
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13855528

IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY

IPC classification:
C07K 1/18, G01N 30/34, G01N 30/96, G01N 33/50
Applicant:
F. Hoffmann-La Roche SA
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP13795394

ENRICHMENT OF ANTIGEN-SPECIFIC PLASMABLASTS

IPC classification:
C07K 16/10, C12N 5/0781, G01N 33/569
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP11720633

COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS

IPC classification:
A61K 39/395, A61K 47/18, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13818602

PREDICTION OF MOLECULAR BIOACTIVATION

IPC classification:
G06F 19/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP11785444

METHODS FOR DETECTING LOW GRADE INFLAMMATION

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14709146

LIQUID CULTURING OF EPITHELIAL STEM CELLS

IPC classification:
C12N 5/071
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11743523

ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, C07K 16/30, G01N 33/53
Applicant:
Roche Glycart AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14717341

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF HEPATIC CANCERS

IPC classification:
A61K 39/00, A61P 35/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14709646

COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES

IPC classification:
C07D 401/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
The patent has been granted
EP14763258

CELL CULTURE MEDIA AND METHODS OF ANTIBODY PRODUCTION

IPC classification:
A61K 39/395, C07K 16/00, C12N 5/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP14721668

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

IPC classification:
C12N 5/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14772646

ANTIBODY FORMULATIONS

IPC classification:
A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP14724046

TRIMERIC ANTIGEN BINDING MOLECULES

IPC classification:
C07K 16/28, C07K 16/40
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP11748847

ANTIBODIES TO IL-1BETA AND IL-18, FOR TREATMENT OF DISEASES

IPC classification:
A61K 39/395, A61P 1/00, A61P 3/10, C07K 16/24, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11796485

ANTI-AXL ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 9/00, A61P 35/00, A61P 37/00, C07K 16/30, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14840968

COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA

IPC classification:
A61K 39/00, A61K 39/395
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
GRANT OF PATENT INTENDED
EP14784169

ANTI-PDL1 ANTIBODY FORMULATIONS

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP11738203

METHOD FOR THE IDENTIFICATION OF CATECHOL O-METHYLTRANSFERASE MODULATORS

IPC classification:
C12Q 1/48, G01N 33/542, G01N 33/573, G01N 33/58
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11794336

LOW AFFINITY ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND THEIR USE TO TRANSFER THERAPEUTIC SCFV ACROSS THE BLOOD BRAIN BARRIER

IPC classification:
A61K 39/395, C07K 16/18, C07K 16/28, C07K 16/40, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP11706799

METHOD FOR DETERMINING THE BINDING CONSTANT OF HIGH AFFINITY COMPOUNDS

IPC classification:
B01D 61/24
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14830759

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY

IPC classification:
A61K 39/395, A61P 35/02, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14833308

METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES

IPC classification:
A61K 31/337, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14824722

DUAL SPECIFIC ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/24, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP16171215

ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER

IPC classification:
A61K 39/395, A61P 35/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Christopher Marcus Denison, Mewburn Ellis LLP
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP10781506

Marker protein for type 2 diabetes

IPC classification:
C07K 16/18, G01N 33/53
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP10798239

ANTI-BV8 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, A61P 35/00, A61P 35/04, C07K 16/22, C07K 16/24
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15706124

ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE

IPC classification:
A61P 35/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP10757138

ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME

IPC classification:
A61K 39/00, A61K 39/395, A61P 35/00, C07K 16/22
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15720712

METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIOMYOCYTES

IPC classification:
C12N 5/077
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15789583

PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS

IPC classification:
A61K 39/00, C12N 5/07, C12P 21/04, C12P 21/08
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15744808

DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15747647

COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15780971

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONIST AND IL-17 BINDING ANTAGONISTS

IPC classification:
A61K 39/00, A61P 35/00, C07K 16/24, C07K 16/28, G01N 33/574
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15772124

ANTIBODY FORMULATIONS

IPC classification:
A61K 39/395, C07K 16/22
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP17155514

METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS

IPC classification:
C12N 5/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
The application has been published
EP15798303

ANIMAL MODEL FOR NEPHROPATHY AND AGENTS FOR TREATING THE SAME

IPC classification:
A01K 67/027, A61K 49/00, C07K 14/775, C07K 16/18, C12N 15/85
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15797972

COMMON LIGHT CHAINS AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15797970

T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AGIANT FOLR1 AND CD3

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/46
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15804652

ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 25/00, C07K 16/28, C07K 16/40, C07K 16/46, C12N 15/13
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15797954

COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES CD3 ABD FOLATE RECEPTOR 1 (FOLR1) AND PD-1 AXIS BINDING ANTAGONISTS

IPC classification:
A61K 39/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15820347

ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF

IPC classification:
A61K 47/69
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15823221

METHODS AND COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS ANTAGONISTS AND HPK1 ANTAGONISTS

IPC classification:
A61K 31/00, A61P 35/00, C07K 16/28
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15816323

ANTI-CD79b ANTIBODIES AND METHODS OF USE

IPC classification:
A61K 39/395, A61P 35/00, A61P 35/02, C07K 16/28, A61K 47/50
Applicant:
F. Hoffmann-La Roche AG
Agent:
Michel Brodbeck, F. Hoffmann-La Roche AG
Status:
Request for examination was made

Please Sign in to use this feature